DECIPHER
PROSTATE **RP**

WHAT IS THE DECIPHER TEST?

Decipher is a tumor-based test that provides genomic information to help you and your physician make decisions about your care

DECIPHER RP

- Performed on your prostate after surgery (after it has been removed)
- May help determine which men after prostate surgery can be safely monitored and which men need additional treatment

ACCESS FOR ALL PATIENTS

- Covered by Medicare
- Covered by select private insurers
- Generous financial assistance program for patients - Decipher Assist

Contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com

Decipher Biosciences
Information for Life

To learn more about Decipher, contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com

DECIPHER
PROSTATE **RP**

AFTER SURGERY

Learn more about your tumor.

Decipher RP helps you and your doctor decide next steps in your prostate cancer care

DECIPHER PROSTATE **RP**

Decipher is a genomic test that is performed on tumor tissue from your prostate.

EVERY TUMOR IS UNIQUE

Decipher provides important information about the underlying biology of your tumor that is not always evident



This test is covered by Medicare and select private insurers. We have a generous financial aid program, Decipher Assist, for qualified patients.

THE DECIPHER TEST:

- Tells you how likely your cancer is to spread (or metastasize) beyond your prostate
- Categorizes most patients into Decipher high or low risk, to help determine what to do after your prostate has been removed (radical prostatectomy)

Contact your doctor to find out how Decipher might play a role in your treatment planning or contact:

Decipher Customer Support Team

» 1.888.792.1601 or

» cs@decipherbio.com

References

1. Den, R. B. et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J. Clin. Oncol. 33, 944–951 (2015).
2. Den, R. B. et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 89, 1038–1046 (2014).
3. Freedland, S. J. et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur. Urol. 70, 588–596 (2016).